A study of Palbociclib in highly pretreated metastatic ER-positive HER-2 negative breast cancer

Trial Profile

A study of Palbociclib in highly pretreated metastatic ER-positive HER-2 negative breast cancer

Active, no longer recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 11 Jan 2018

At a glance

  • Drugs Palbociclib (Primary) ; Anastrozole; Exemestane; Fulvestrant; Megestrol; Tamoxifen
  • Indications Advanced breast cancer
  • Focus Expanded access; Therapeutic Use
  • Most Recent Events

    • 11 Jan 2018 New trial record
    • 09 Dec 2017 An updated data will be presented at conference.
    • 09 Dec 2017 Results (n=68) of retrospective analysis assessing safety and efficacy presented at the 40th Annual San Antonio Breast Cancer Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top